Nebula Research & Development LLC Has $994,000 Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Nebula Research & Development LLC lifted its holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 92.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 36,239 shares of the company's stock after purchasing an additional 17,400 shares during the period. Nebula Research & Development LLC's holdings in BridgeBio Pharma were worth $994,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in the business. Vanguard Group Inc. increased its position in BridgeBio Pharma by 6.2% in the 4th quarter. Vanguard Group Inc. now owns 15,077,915 shares of the company's stock worth $413,738,000 after buying an additional 879,059 shares during the period. Capital Research Global Investors increased its position in BridgeBio Pharma by 34.9% during the fourth quarter. Capital Research Global Investors now owns 3,526,747 shares of the company's stock worth $96,774,000 after acquiring an additional 912,439 shares during the period. Charles Schwab Investment Management Inc. raised its stake in BridgeBio Pharma by 1.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,306,765 shares of the company's stock valued at $35,858,000 after purchasing an additional 21,963 shares during the last quarter. Emerald Advisers LLC boosted its holdings in BridgeBio Pharma by 4.3% in the 4th quarter. Emerald Advisers LLC now owns 1,150,868 shares of the company's stock valued at $31,580,000 after purchasing an additional 47,360 shares during the period. Finally, Principal Financial Group Inc. grew its position in BridgeBio Pharma by 1.8% in the 3rd quarter. Principal Financial Group Inc. now owns 1,145,123 shares of the company's stock worth $29,155,000 after purchasing an additional 19,978 shares during the last quarter. Institutional investors and hedge funds own 99.85% of the company's stock.

Insiders Place Their Bets

In related news, CEO Neil Kumar sold 31,543 shares of the business's stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $36.14, for a total transaction of $1,139,964.02. Following the completion of the sale, the chief executive officer now directly owns 211,718 shares of the company's stock, valued at $7,651,488.52. The trade was a 12.97 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, major shareholder Global Investors Lp Viking sold 3,065,616 shares of the firm's stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $34.90, for a total transaction of $106,989,998.40. Following the completion of the transaction, the insider now directly owns 22,055,375 shares in the company, valued at approximately $769,732,587.50. The trade was a 12.20 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 9,374,807 shares of company stock valued at $315,534,819. 24.66% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of analysts have commented on the company. Cantor Fitzgerald reiterated an "overweight" rating and issued a $95.00 price objective on shares of BridgeBio Pharma in a research report on Friday, February 21st. UBS Group lifted their price target on shares of BridgeBio Pharma from $65.00 to $72.00 and gave the stock a "buy" rating in a research note on Wednesday. HC Wainwright lifted their target price on shares of BridgeBio Pharma from $49.00 to $53.00 and gave the company a "buy" rating in a research report on Tuesday, April 15th. Redburn Atlantic started coverage on shares of BridgeBio Pharma in a research note on Monday, March 31st. They set a "buy" rating and a $50.00 price target for the company. Finally, Piper Sandler upped their price objective on BridgeBio Pharma from $46.00 to $63.00 and gave the company an "overweight" rating in a research note on Wednesday. One research analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $57.09.

BridgeBio Pharma Trading Up 5.3 %

Shares of BridgeBio Pharma stock traded up $1.94 during trading on Wednesday, reaching $38.36. The company's stock had a trading volume of 10,833,327 shares, compared to its average volume of 2,329,093. The stock has a 50-day moving average price of $33.90 and a two-hundred day moving average price of $30.61. The stock has a market capitalization of $7.28 billion, a P/E ratio of -13.46 and a beta of 1.08. BridgeBio Pharma, Inc. has a one year low of $21.62 and a one year high of $40.72.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last announced its earnings results on Tuesday, April 29th. The company reported ($0.88) earnings per share for the quarter, topping analysts' consensus estimates of ($1.00) by $0.12. The company had revenue of $36.74 million during the quarter, compared to the consensus estimate of $57.14 million. During the same period in the prior year, the firm posted ($0.20) earnings per share. The company's revenue was down 44.8% on a year-over-year basis. As a group, sell-side analysts anticipate that BridgeBio Pharma, Inc. will post -3.67 EPS for the current fiscal year.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.